Lv2
146 积分 2023-12-14 加入
Neoadjuvant and Adjuvant Therapies for High-Risk Prostate Cancer
21小时前
求助中
First PROTAC gains FDA approval, bolstering targeted protein degradation and induced proximity ambitions
5天前
已完结
Impact of Absolute PSA Value and Relative PSA Response Rate on Overall Survival in Patients With Metastatic Castration‐Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors
7天前
已完结
A Watershed Moment in the Perioperative Treatment of Prostate Cancer
7天前
已完结
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer
7天前
已完结
Two decades of PARP inhibitor synthetic lethality in cancer
8天前
已完结
Does the PSA test for prostate cancer save lives? New data reverse gold-standard findings
8天前
已关闭
Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial
8天前
已完结
Real-World Clinical and Economic Outcomes Among Patients with Localized Prostate Cancer Undergoing Radical Prostatectomy Across Different Risk Stratifications in the United States
8天前
已完结
Neoadjuvant and Adjuvant Therapies for High-Risk Prostate Cancer
9天前
已关闭
皖公网安备34019202002308
